These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Wnt/β-catenin signaling as an emerging potential key pharmacological target in cholangiocarcinoma. Zhang GF; Qiu L; Yang SL; Wu JC; Liu TJ Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32140709 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of Wnt/β-catenin signaling downregulates P-glycoprotein and reverses multi-drug resistance of cholangiocarcinoma. Shen DY; Zhang W; Zeng X; Liu CQ Cancer Sci; 2013 Oct; 104(10):1303-8. PubMed ID: 23822562 [TBL] [Abstract][Full Text] [Related]
4. Long non-coding RNA MIR22HG inhibits cell proliferation and migration in cholangiocarcinoma by negatively regulating the Wnt/β-catenin signaling pathway. Hu X; Tan Z; Yang Y; Yang P J Gene Med; 2019 May; 21(5):e3085. PubMed ID: 30856284 [TBL] [Abstract][Full Text] [Related]
6. Opisthorchis viverrini infection activates the PI3K/ AKT/PTEN and Wnt/β-catenin signaling pathways in a Cholangiocarcinogenesis model. Yothaisong S; Thanee M; Namwat N; Yongvanit P; Boonmars T; Puapairoj A; Loilome W Asian Pac J Cancer Prev; 2014; 15(23):10463-8. PubMed ID: 25556493 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of ClC-5 suppresses proliferation and induces apoptosis in cholangiocarcinoma cells through the Wnt/β-catenin signaling pathway. Shi Z; Zhou L; Zhou Y; Jia X; Yu X; An X; Han Y BMB Rep; 2022 Jun; 55(6):299-304. PubMed ID: 35651328 [TBL] [Abstract][Full Text] [Related]
8. Upregulation of TTYH3 promotes epithelial-to-mesenchymal transition through Wnt/β-catenin signaling and inhibits apoptosis in cholangiocarcinoma. Xue W; Dong B; Zhao Y; Wang Y; Yang C; Xie Y; Niu Z; Zhu C Cell Oncol (Dordr); 2021 Dec; 44(6):1351-1361. PubMed ID: 34796468 [TBL] [Abstract][Full Text] [Related]
9. The inhibition of β-catenin activity by luteolin isolated from Paulownia flowers leads to growth arrest and apoptosis in cholangiocarcinoma. Yang H; Zhao Y; Song W; Fan G Int J Biol Macromol; 2024 Jan; 254(Pt 1):127627. PubMed ID: 37884243 [TBL] [Abstract][Full Text] [Related]
10. Guanine nucleotide exchange factor T exerts the cancer-promoting function in cholangiocarcinoma by enhancing the Wnt-GSK-3β-β-catenin cascade via regulation of Rac1/Cdc42. Wang X; Zhang X; Sun J; Sun Y; Zhang Y; He L; Wang P; Li F; Sun C Toxicol Appl Pharmacol; 2023 May; 467():116492. PubMed ID: 36977438 [TBL] [Abstract][Full Text] [Related]
11. Retinoid X receptor α enhances human cholangiocarcinoma growth through simultaneous activation of Wnt/β-catenin and nuclear factor-κB pathways. Huang GL; Zhang W; Ren HY; Shen XY; Chen QX; Shen DY Cancer Sci; 2015 Nov; 106(11):1515-23. PubMed ID: 26310932 [TBL] [Abstract][Full Text] [Related]
12. Oncogenic activity of retinoic acid receptor γ is exhibited through activation of the Akt/NF-κB and Wnt/β-catenin pathways in cholangiocarcinoma. Huang GL; Luo Q; Rui G; Zhang W; Zhang QY; Chen QX; Shen DY Mol Cell Biol; 2013 Sep; 33(17):3416-25. PubMed ID: 23798555 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of Wnt signaling induces cell apoptosis and suppresses cell proliferation in cholangiocarcinoma cells. Zhang KS; Zhou Q; Wang YF; Liang LJ Oncol Rep; 2013 Sep; 30(3):1430-8. PubMed ID: 23799613 [TBL] [Abstract][Full Text] [Related]
15. miR-191 Inhibition Induces Apoptosis Through Reactivating Secreted Frizzled-Related Protein-1 in Cholangiocarcinoma. Kang PC; Leng KM; Liu YP; Liu Y; Xu Y; Qin W; Gao JJ; Wang ZD; Tai S; Zhong XY; Cui YF Cell Physiol Biochem; 2018; 49(5):1933-1942. PubMed ID: 30235453 [TBL] [Abstract][Full Text] [Related]
16. Bufalin targeting CAMKK2 inhibits the occurrence and development of intrahepatic cholangiocarcinoma through Wnt/β-catenin signal pathway. Zhang H; Dong X; Ding X; Liu G; Yang F; Song Q; Sun H; Chen G; Li S; Li Y; Wang M; Guo T; Zhang Z; Li B; Yang L J Transl Med; 2023 Dec; 21(1):900. PubMed ID: 38082327 [TBL] [Abstract][Full Text] [Related]
17. γ-aminobutyric acid B2 receptor: A potential therapeutic target for cholangiocarcinoma in patients with diabetes mellitus. Saengboonmee C; Sorin S; Sangkhamanon S; Chomphoo S; Indramanee S; Seubwai W; Thithuan K; Chiu CF; Okada S; Gingras MC; Wongkham S World J Gastroenterol; 2023 Jul; 29(28):4416-4432. PubMed ID: 37576707 [TBL] [Abstract][Full Text] [Related]
18. β-escin reverses multidrug resistance through inhibition of the GSK3β/β-catenin pathway in cholangiocarcinoma. Huang GL; Shen DY; Cai CF; Zhang QY; Ren HY; Chen QX World J Gastroenterol; 2015 Jan; 21(4):1148-57. PubMed ID: 25632187 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of potential targets to enhance the sensitivity of cholangiocarcinoma cells to anticancer drugs. Sanchon-Sanchez P; Briz O; Macias RIR; Abad M; Sanchez-Martin A; Marin JJG; Lozano E Biomed Pharmacother; 2023 Dec; 168():115658. PubMed ID: 37832404 [TBL] [Abstract][Full Text] [Related]
20. Forced overexpression of FBP1 inhibits proliferation and metastasis in cholangiocarcinoma cells via Wnt/β-catenin pathway. Zhao W; Yang S; Chen J; Zhao J; Dong J Life Sci; 2018 Oct; 210():224-234. PubMed ID: 30193944 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]